Marksans Pharma Ltd.

NSE: MARKSANS  SECTOR: Pharmaceuticals & Drugs

58.95
+1.05 (1.81%)

Price Summary

Today's High

₹ 59.35

Today's Low

₹ 57.35

52 Week High

₹ 62.65

52 Week Low

₹ 9.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

2412.90424971 Cr.

Enterprise Value

2409.59775291 Cr.

No. of Shares

40.9313698 Cr.

P/E

36.57

P/B

4.41

Face Value

₹ 1

Div. Yield

0.17%

Book Value (TTM)

₹  13.3691

CASH

3.352321 Cr.

DEBT

0.0458242 Cr.

Promoter Holding

48.25%

EPS (TTM)

₹  1.6119

Sales Growth

2.18192267209927%

ROE

7.76549882596146 %

ROCE

11.3900556886487 %

Profit Growth

8.74528540217541 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year2.18%
3 Year26.16%
5 Year1.34%

Profit Growth (in Cr.)

1 Year-13.1%
3 Year48.63%
5 Year-10.8%

ROE%

1 Year7.77%
3 Year6.8%
5 Year8.42%

ROCE %

1 Year11.39%
3 Year9.43%
5 Year10.84%

Debt/Equity

0.0001

Price to Cash Flow

20.45

Interest Cover Ratio

8.23106411875313

CFO/PAT (5 Yr. Avg.)

0.910300400711092

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2019 48.25 0
Sep 2019 48.25 0
Jun 2019 48.25 0
Mar 2019 48.25 0
Dec 2018 48.25 0
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 48.6251912881789% for the Past 3 years.
  • The company has shown a good revenue growth of 26.1603862520469% for the Past 3 years.
  • The company has significantly decreased its debt by 77.5889721 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 8.23106411875313.
  • Company has a healthy liquidity position with current ratio of 3.50847216436325.
  • The company has a good cash flow management; CFO/PAT stands at 0.910300400711092.

 Limitations

  • Company has a poor ROE of 6.79821593968138% over the past 3 years.
  • Company has contingent liabilities of 140.3790107 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020
Net Sales 100.72 116.88 113.64 155.96 137.55
Total Expenditure 87.92 96.62 95.25 126.96 114.5
Operating Profit 12.79 20.26 18.39 29 23.05
Other Income 7.87 0.01 -0.08 0.05 12.96
Interest 2.47 1.26 1.67 0.79 1.32
Depreciation 2.66 2.88 3.46 3.34 3.67
Exceptional Items 0 0 0 0 0
Profit Before Tax 15.53 16.12 13.17 24.92 31.01
Tax 3.66 3.15 5.76 2.87 7.48
Profit After Tax 11.86 12.98 7.41 22.06 23.54
Adjusted EPS (Rs) 0.03 0.03 0.02 0.05 0.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 358.13 215.84 294.66 424.16 433.42
Total Expenditure 258.76 202.15 265.52 360.83 361.93
Operating Profit 99.38 13.69 29.15 63.33 71.49
Other Income 13.21 17.75 7.43 7.93 0.17
Interest 6.2 4.49 7.67 6.56 7.29
Depreciation 14.75 15 12.25 8.69 11.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 91.63 11.95 16.65 56.01 52.73
Tax 20.14 0.4 4.23 12.39 14.82
Net Profit 71.49 11.55 12.43 43.62 37.9
Adjusted EPS (Rs.) 1.75 0.28 0.3 1.07 0.93

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 53.43 40.93 40.93 40.93 40.93
Total Reserves 369.27 377.95 388.04 429.64 464.69
Borrowings 0 0 0 0 0
Other N/C liabilities 0.31 17.3 17.09 18.39 28.03
Current liabilities 111.19 109.59 111.22 133.39 71.9
Total Liabilities 534.2 545.77 557.29 622.35 605.55
Assets
Net Block 97.47 93.92 87.89 102.61 115.18
Capital WIP 0 0.36 0 0 0
Investments 231.44 234.29 236.07 236.07 236.07
Loans & Advances 1.25 0.59 0.82 1.29 2.05
Other N/C Assets 0 0 0 0 0
Current Assets 204.04 216.61 232.51 282.37 252.25
Total Assets 534.2 545.77 557.29 622.35 605.55
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 91.63 11.95 16.65 56.01 52.73
Adjustment 8.82 12.5 20 11.57 19.17
Working Capital Changes -15.35 -22.39 -16.33 -34.91 56.6
Tax Paid -20.33 -15.69 -4.68 -12.86 -10.49
Operating Cash Flow 64.76 -13.62 15.63 19.81 118.01
Investing Cash Flow -177.34 -7.69 -7.55 -20.2 -24.1
Financing Cash Flow -51.83 20.74 -9.98 0.96 -92.29
Net Cash Flow -164.41 -0.57 -1.9 0.56 1.63

Corporate Actions

Ratings & Research Reports

Company Presentations

Company News

Marksans Pharma Stock Price Analysis and Quick Research Report. Is Marksans Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Marksans Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 118.0141634 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Marksans Pharma has a Debt to Equity ratio of 0.0001 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Marksans Pharma , the EPS growth was -13.1006006006006 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Marksans Pharma has OPM of 16.4944921825364 % which is a good sign for profitability.
     
  • ROE: Marksans Pharma have a poor ROE of 7.76549882596146 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Marksans Pharma

X